参考文献/References:
[1]St Louis EK,Boeve AR,Boeve BF.REM Sleep Behavior Disorder in Parkinson’s Disease and Other Synucleinopathies[J].Mov Disord,2017,32(5):645-658.[2]刘军.中国帕金森病的诊断标准(2016版)[J].中华神经科杂志,2016,49(4):268-271.[3]王文婷,陈鸿旭,李娅,等.伴快速眼动睡眠行为障碍帕金森病患者临床特点及自主神经功能障碍变化[J].中国神经免疫学和神经病学杂志,2019,26(3):153-157.[4]黄小冬.帕金森病伴快速眼动睡眠行为障碍的临床特征研究[D].昆明:昆明医科大学,2019.[5]Pagano G,De Micco R,Yousaf T,et al.REM behavior disorder predicts motor progression and cognitive decline in Parkinson disease[J].Neurology,2018,91(10):e894-e905.[6]Leclair-Visonneau L,Clairembault T,Coron E,et al.REM sleep behavior disorder is related to enteric neuropathology in Parkinson disease[J].Neurology,2017,89(15):1612-1618.[7]Shprecher DR,Adler CH,Zhang N,et al.Predicting alpha-synuclein pathology by REM sleep behavior disorder diagnosis[J].Parkinsonism Relat Disord,2018(55):92-96.[8]Valli M,Cho SS,Uribe C,et al.VMAT2 availability in Parkinson’s disease with probable REM sleep behaviour disorder[J].Mol Brain,2021,14(1):165.[9]Sommerauer M,Fedorova TD,Hansen AK,et al.Evaluation of the noradrenergic system in Parkinson’s disease: an 11C-MeNER PET and neuromelanin MRI study[J]. Brain,2018,141(2):496-504.[10]Wilson H,Giordano B,Turkheimer FE,et al.Serotonergic dysregulation is linked to sleep problems in Parkinson’s disease[J].Neuroimage Clin,2018(18):630-637.[11]Xu Q,Jiang C,Ge J,et al.The impact of probable rapid eye movement sleep behavior disorder on Parkinson’s disease: A dual-tracer PET imaging study[J].Parkinsonism Relat Disord,2021(95):47-53.[12]苗蕾,徐瑛,王建民,等.经颅彩色超声参数在帕金森病诊断中应用价值[J].临床军医杂志,2021,49(1):50-51,54.[13]Zhou HY,Huang P,Sun Q,et al.Substantia Nigra Echogenicity Associated with Clinical Subtypes of Parkinson’s Disease[J].J Parkinsons Dis,2018,8(2):333-340.[14]Maskova J,Skoloudik D,Stofaniková P,et al.Comparative study of the substantia nigra echogenicity and 123I-Ioflupane SPECT in patients with synucleinopathies with and without REM sleep behavior disorder[J].Sleep Med,2020(70):116-123.[15]Zhang S,Tao K,Wang J,et al.Substantia Nigra Hyperechogenicity Reflects the Progression of Dopaminergic Neurodegeneration in 6-OHDA Rat Model of Parkinson’s Disease[J].Front Cell Neurosci,2020(14):216.[16]Rahayel S,Gaubert M,Postuma RB,et al.Brain atrophy in Parkinson’s disease with polysomnography-confirmed REM sleep behavior disorder[J].Sleep,2019,42(6):zsz062.[17]Lim JS,Shin SA,Lee JY,et al.Neural substrates of rapid eye movement sleep behavior disorder in Parkinson’s disease[J].Parkinsonism Relat Disord,2016(23):31-36.[18]Boucetta S,Salimi A,Dadar M,et al.Structural Brain Alterations Associated with Rapid Eye Movement Sleep Behavior Disorder in Parkinson’s Disease[J].Sci Rep,2016(6):26782.[19]Kamps S,van den Heuvel OA,van der Werf YD,et al.Smaller subcortical volume in Parkinson patients with rapid eye movement sleep behavior disorder[J].Brain Imaging Behav,2019,13(5):1352-1360.[20]Hu Y,Yu SY,Zuo LJ,et al.Investigation on Abnormal Iron Metabolism and Related Inflammation in Parkinson Disease Patients with Probable RBD[J].PLoS One,2015,10(10):e0138997.[21]张佳.帕金森病快动眼睡眠行为障碍的临床特征及其与血清铁代谢相关蛋白的关系[D].大连:大连医科大学,2019.[22]扈杨,余舒扬,左丽君,等.帕金森病患者伴发很可能的快速眼动睡眠行为障碍的铁代谢异常及神经免疫炎症机制的研究[C].//中国微循环学会神经变性病专业委员会第五届学术年会暨第二届北京国际神经变性病学术大会、北京神经变性病学会第一届学术会议论文集.2017:1-2.[23]Guan X,Xuan M,Gu Q,et al.Regionally progressive accumulation of iron in Parkinson’s disease as measured by quantitative susceptibility mapping[J].NMR Biomed,2017,30(4):10.1002/nbm.3489.[24]Chen Q,Chen Y,Zhang Y,et al.Iron deposition in Parkinson’s disease by quantitative susceptibility mapping[J].BMC Neurosci,2019,20(1):23.[25]Pyatigorskaya N,Gaurav R,Arnaldi D,et al.Magnetic Resonance Imaging Biomarkers to Assess Substantia Nigra Damage in Idiopathic Rapid Eye Movement Sleep Behavior Disorder[J].Sleep,2017,40(11):28958075.[26]Schindlbeck KA,Eidelberg D.Network imaging biomarkers: insights and clinical applications in Parkinson’s disease[J].Lancet Neurol,2018,17(7):629-640.[27]Li D,Huang P,Zang Y,et al.Abnormal baseline brain activity in Parkinson’s disease with and without REM sleep behavior disorder: A resting-state functional MRI study[J].J Magn Reson Imaging,2017,46(3):697-703.
相似文献/References:
[1]王姝,莫英绪,王大成.帕金森病发病因素的研究现状[J].医学信息,2018,31(01):46.[doi:10.3969/j.issn.1006-1959.2018.01.017]
WANG Shu,MO Ying-xu,WANG Da-cheng.Research Status of the Factors of Parkinson's Disease[J].Medical Information,2018,31(02):46.[doi:10.3969/j.issn.1006-1959.2018.01.017]
[2]刘 阳,王惠凌,安 迪,等.进行性核上性麻痹1例报告[J].医学信息,2018,31(05):192.[doi:10.3969/j.issn.1006-1959.2018.05.073]
[3]樊 毅.帕金森病嗅觉改变的相关性研究[J].医学信息,2018,31(17):95.[doi:10.3969/j.issn.1006-1959.2018.17.029]
FAN Yi.Correlation Study of Olfactory Changes in Parkinson's Disease[J].Medical Information,2018,31(02):95.[doi:10.3969/j.issn.1006-1959.2018.17.029]
[4]侯晓丽,张亚慧,唐迎乐.人参皂苷Rg3对帕金森病模型大鼠多巴胺能神经元氧化应激的抑制作用[J].医学信息,2023,36(19):88.[doi:10.3969/j.issn.1006-1959.2023.19.018]
HOU Xiao-li,ZHANG Ya-hui,TANG Ying-le.Inhibitory Effect of Ginsenoside Rg3 on Oxidative Stress in Dopaminergic Neurons of Parkinson’s Disease Model Rats[J].Medical Information,2023,36(02):88.[doi:10.3969/j.issn.1006-1959.2023.19.018]
[5]陈凤全.帕金森病的诊治现状及进展[J].医学信息,2020,33(12):43.[doi:10.3969/j.issn.1006-1959.2020.12.014]
CHEN Feng-quan.Status and Progress of Diagnosis and Treatment of Parkinson’s Disease[J].Medical Information,2020,33(02):43.[doi:10.3969/j.issn.1006-1959.2020.12.014]
[6]张 磊,张巧俊,惠艳娉.经颅直流电刺激调控帕金森病抑郁相关的脑环路及机制[J].医学信息,2022,35(21):159.[doi:10.3969/j.issn.1006-1959.2022.21.043]
ZHANG Lei,ZHANG Qiao-jun,HUI Yan-ping.Transcranial Direct Current Stimulation Regulates Depression-related Brain Circuits and Mechanism in Parkinson’s Disease[J].Medical Information,2022,35(02):159.[doi:10.3969/j.issn.1006-1959.2022.21.043]
[7]邓伟胜,楼云龙,苏中振.正电子发射断层扫描PET/CT在帕金森病患者早期诊断中的应用[J].医学信息,2020,33(18):170.[doi:10.3969/j.issn.1006-1959.2020.18.057]
DENG Wei-sheng,LOU Yun-long,SU Zhong-zhen.Application of Positron Emission Tomography PET/CT in Early Diagnosis of Parkinson’s Disease[J].Medical Information,2020,33(02):170.[doi:10.3969/j.issn.1006-1959.2020.18.057]
[8]贺诗佳,孙 玲,张树山.脑内肾素-血管紧张素系统在帕金森病发病机制中的作用研究[J].医学信息,2021,34(03):34.[doi:10.3969/j.issn.1006-1959.2021.03.011]
HE Shi-jia,SUN Ling,ZHANG Shu-shan.Study on the Role of Renin-angiotensin System in the Pathogenesis of Parkinson’s Disease[J].Medical Information,2021,34(02):34.[doi:10.3969/j.issn.1006-1959.2021.03.011]
[9]许红玉,梅育嘉,罗杰峰.神经节苷脂联合复方左旋多巴治疗帕金森病的效果[J].医学信息,2021,34(03):160.[doi:10.3969/j.issn.1006-1959.2021.03.045]
XU Hong-yu,MEI Yu-jia,LUO Jie-feng.The Effect of Ganglioside Combined with Benserazide in the Treatment of Parkinson’s Disease[J].Medical Information,2021,34(02):160.[doi:10.3969/j.issn.1006-1959.2021.03.045]
[10]胡方婷,薛冬辉.运动-心理-睡眠护理干预对帕金森病患者负性情绪的影响[J].医学信息,2021,34(05):181.[doi:10.3969/j.issn.1006-1959.2021.05.053]
HU Fang-ting,XUE Dong-hui.Effects of Exercise-psychological-sleep Nursing Intervention on Negative Emotions in Patients with Parkinson’s Disease[J].Medical Information,2021,34(02):181.[doi:10.3969/j.issn.1006-1959.2021.05.053]